Anthem Biosciences Limited announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported consolidated revenue from operations for the nine months of FY26 at ₹15,134 million, with EBITDA at ₹6,712 million (41.5% margin) and PAT at ₹4,020 million (24.8% margin). For the third quarter of FY26, consolidated revenue from operations stood at ₹4,232 million. EBITDA for the quarter was ₹1,907 million (41.8% margin), and PAT was ₹928 million (20.3% margin). The company's CRDMO business contributed ₹12,599 million in revenues for the nine months and ₹3,332 million for the quarter, while Specialty Ingredients contributed ₹2,535 million for the nine months and ₹899 million for the quarter. An exceptional item of ₹254 million was recorded for the nine months and the quarter, related to the impact of new labor codes notified by the Government of India. The company has assessed and made a provision in accordance with the guidance from the Institute of Chartered Accountants of India. As of December 31, 2025, Anthem Biosciences maintained a net cash position of ₹312,312 million. Ajay Bhardwaj, Chairman, MD and CEO, commented that the 9MFY26 performance showed steady progress in revenue and an improving margin profile, with EBITDA growing at 23% and PBT before exceptional items growing around 20%. He expressed confidence in delivering a strong finish to the financial year, despite a higher base in the same quarter last year, noting that underlying demand remains robust.
